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Desmoid tumors are benign mesenchymal tumors with a strong tendency for local recurrence after surgery.
Radiotherapy improves local control following incomplete resection, but nearby organs at risk may limit the dose to
the target volume. The patient in this report presented with a recurrent desmoid tumor of the right flank and
underwent surgery with microscopically positive margins. Particular problems presented in this case included that
the tumor bed was situated in close proximity to the liver and the right kidney and that the right kidney was
responsible for 65% of the patient’s renal function. Intensity-modulated radiation therapy plans delivering 54 Gy
necessarily exposed the right kidney to a V18 of 98% and the liver to a V30 of 55%. Proton therapy plans significantly
reduced the right kidney V18 to 32% and the liver V30 to 28%. In light of this, the proton plan was utilized for
treatment of this patient. Proton therapy was tolerated without gastrointestinal discomfort or other complaints.
Twenty-four months after initiation of proton therapy, the patient is without clinical or radiographic evidence of
disease recurrence. In this setting, the improved dose distribution associated with proton therapy allowed for
curative treatment of a patient who arguably could not have been safely treated with intensity-modulated radiation
therapy or other methods of conventional radiotherapy.
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Desmoid tumor (DT) is a deep-seated fibroblastic neo-
plasm that arises from musculoaponeurotic stromal tis-
sue. It exhibits slow growth with a strong tendency for
local recurrence (LR) and a low metastatic potential. DTs
can arise anywhere in the body, but commonly occur in
the proximal extremities, trunk, and abdominal wall. Sur-
gery remains the primary treatment for DT with a goal of
gross total resection with wide surgical margins. Because
of the infiltrative growth pattern of DT, surgical resection
alone is associated with a significant LR rate of 24% to
77% [1-3]. Several studies have suggested lower LR rates
when adjuvant radiation therapy (RT) is employed [4-6].
Previously, our institution reported improved local-
regional control in patients with DT receiving a total
radiation dose ≥ 55 Gy after surgical resection [7]. While* Correspondence: rnichols@floridaproton.org
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reproduction in any medium, provided the ordelivering doses in the range of 55 Gy to extremity lesions
can be achieved with 3-dimensioanl conformal RT
(3DCRT) or intensity-modulated RT (IMRT) using x-rays
- since the targets are generally located away from critical
radiosensitive tissues - delivering such doses to truncal
targets is more difficult due to the proximity of highly
radiosensitive organs, such as the lungs, spinal cord,
intestines, liver and kidneys.
Proton therapy (PT) has the potential to improve the
therapeutic index in such a setting compared to conven-
tional x-ray-based therapy. While x-rays pass through
the patient and leave a track of exposure from the en-
trance surface to the exit surface of the patient, protons
(which are particles with mass) can be accelerated to
penetrate into tissue only to the depth of the target.
When patients are treated with proton-based radiother-
apy most of the radiation energy is discharged at a
discrete and predictable depth called the Bragg peak. A
"spread-out Bragg peak" can be created to match theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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present here demonstrates a situation where the
improved therapeutic index associated with PT allowed
for the potentially curative treatment of a patient who
arguably could not have been safely treated with x-rays.
Case presentation
A 36-year-old white female self-detected a mass in
the right flank. Magnetic resonance imaging (MRI)
demonstrated a 7.3 × 4-cm lobulated mass along the
right posterior-lateral abdominal wall at the level of
the right kidney (Figure 1A). Incisional biopsy was per-
formed followed by surgical resection. Final resection
margins were microscopically negative. Postoperative
MRI of the abdomen demonstrated no residual mass in
the right flank (Figure 1B). No adjuvant treatment was
recommended.
Approximately 12 months after the surgical resection,
the patient noticed a palpable lump in the surgical bed.
MRI of the abdomen revealed a 6.5 × 2.8-cm mass
involving the right flank with an associated abdominal
wall hernia (Figure 1C). Salvage surgery was performed
to remove the recurrent mass and repair the hernia.
Final histopathology again revealed a benign DT. The
microscopic surgical margin was focally positive. The
patient’s case was presented at a multidisciplinary tumor
board with the recommendation that she receiveFigure 1 Serial magnetic resonance imaging (MRI) scans. (A) Taken at
right posterior-lateral abdominal wall at the level of the flank and right kidn
(C) Taken 12 months after the initial surgery. The red arrow indicates 6.5 ×
months after completing proton therapy. No evidence of re-recurrence ofadjuvant radiotherapy based on the tumor’s recurrent
nature and the presence of positive margins.
At her initial radiation oncology consultation, the
patient demonstrated a long, horizontal incision in the
right posterolateral aspect of the abdominal wall that was
healing. No suspicious palpable abnormality was appre-
ciated. Given the proximity of the tumor bed to the right
kidney, split renal function studies were ordered. Labora-
tory data showed that blood urea nitrogen and creatinine
levels to be within normal ranges (8.0 mg/dL and 0.49
mg/dL, respectively) as well as a glomerular filtration rate
of > 60 mL per minute. A nuclear renal scan using Tc-
99m MAG3 demonstrated decreased flow and uptake
within the left kidney compared to the right kidney
(Figure 2). The right kidney was the dominant kidney,
comprising 65% of the patient’s renal function. The risks
and benefits of adjuvant external-beam RT in this context
were discussed with the patient who elected to pursue
adjuvant radiotherapy.
For the RT, an optimized IMRT plan was generated to
deliver a dose of 54 Gy (1.8 Gy per fraction) to the
tumor bed (Figure 3A). The planning target volume
(PTV) consisted of the initial tumor bed plus the recur-
rent tumor bed with an approximately 6-cm margin on
the abdominal wall (but not extending into the abdom-
inal cavity). Ninety-five percent of the PTV volume
received 100% of the prescribed target dose and 100% ofthe initial diagnosis. The red arrow indicates 7.3 × 4-cm mass on the
ey. (B) Taken after the initial surgery, showing no evidence of disease.
2.8-cm recurrent mass on the previous surgical bed. (D) Taken at 24
the tumor.
Figure 2 A nuclear renal scan after intravenous injection of 11.085 mCi of Tc-99m MAG3. There is decreased flow and uptake within the
left kidney compared to the right. Differential renal function is 35% for the left kidney and 65% for the right kidney. There is prompt bilateral
excretion with a transit time of three minutes. No evidence of obstruction.
Figure 3 Colorwash comparisons of the intensity-modulated radiotherapy (IMRT) and proton plans to deliver 59.40 Gy or 59.40 Cobalt
Gray Equivalent (CGE) to the planning target volume (PTV). Dose-volume histograms (DVH) for these plans are shown in Figure 4.
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Normal-tissue goals of particular interest were as follows:
right kidney V18 (volume receiving ≥ 18 Gy) to < 70%;
left kidney V18 to < 30%; liver V30 Gy to < 50%; and
spinal cord maximum to < 46 Gy. IMRT plans delivering
54 Gy to the PTV, however, necessarily exposed the 98%
of the right kidney to ≥ 18 Gy and 55% of the liver to
≥ 30 Gy. Minimizing the right kidney dose was neces-
sarily prioritized because the right kidney was the
dominant kidney and responsible for 65% of the
patient’s renal function.
To deliver a high dose of radiation to the PTV without
compromising the function of the right kidney, PT plans
were then generated. The clinical target volume (CTV)
and PTV were identical. The proton plan utilized two
fields that included posterior-anterior and right posterior-
oblique fields. The CTV and PTV coverages were iden-
tical. Dose was prescribed in cobalt Gy equivalent
(CGE) by use of a relative biological effectiveness of 1.1.
The proton plan reduced the right kidney V18 to 32%
and the liver V30 to 28% without adversely affectingFigure 4 Dose-volume histogram (DVH) data for the proton plan (del
radiotherapy (IMRT) plan shown in Figure 3. The planning target volum
proton plan. Normal-tissue exposures for the proton plan were 32% for the
tissue exposures for the IMRT plan were 98% for the right kidney V18 Gy aother critical organs or compromising target coverage
(Figure 3B). Additional benefits from the PT plan com-
pared to the photon IMRT plan included sparing the
left kidney from any radiation exposure and lowering
the integral dose to the body. In light of these advan-
tages, the PT plan was recommended.
The initial PT plan was to deliver 54 CGE (1.8 CGE
per fraction) to the PTV. The patient, however, had a
family emergency, resulting in a 2-week treatment delay
after delivery of 5.4 CGE. Therefore, the final PTV dose
was increased to 59.4 CGE over 33 fractions. Normal-
tissue exposures for the PT plan compared to the
photon IMRT plan were as follows (with hypothetical
optimized IMRT exposures in parentheses): mean liver
dose, 17.6 CGE (versus 36.1 Gy); mean right kidney
dose, 18.9 CGE (versus 38.8 Gy); mean spinal cord dose,
0.1 CGE (versus 18.9 Gy) (Figure 4). The integral dose
to the body was lower with protons, particularly in the
low dose range, with greater than a 5-fold reduction in
the volume of uninvolved normal tissues receiving a
dose of 10 Gy (Figure 5).ivered) and the corresponding optimized intensity-modulated
e (PTV) dose was 59.40 Gy for the IMRT plan and 59.40 CGE for the
right kidney V18 CGE and 28% for the liver V30 CGE 28%. Normal-
nd 55% for the liver V30 Gy.
Figure 5 DVH demonstrates reduced total body dose with protons, notably in the low-dose range.
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out nausea or other gastrointestinal discomfort. Her only
measurable toxicity was grade 1 skin erythema without
desquamation in the treated field. Her blood urea nitro-
gen and creatinine levels were 10.0 mg/dL and 0.7 mg/
dL, respectively, with a glomerular filtration rate of
greater than 101.2 mL per minute at the completion of
PT. Her most recent physical examination 24 months
after treatment demonstrates no palpable mass and no
skin toxicity. She is without any gastrointestinal toxicity
and is working full-time. MRI of the abdomen at 24
months after initiation of PT demonstrates no evidence
of recurrent disease (Figure 1D).
Discussion
DTs are benign tumors with locally aggressive growth
and a high rate of recurrence after surgical resection.
Adjuvant postoperative RT is regularly utilized at our in-
stitution to reduce recurrence risk. A previous study
published by the University of Florida evaluating the
local-regional control of DTs in an adult cohort showed
a 5-year local-regional control rate of 83% [7]. Proton
therapy has been demonstrated to reduce gastrointes-
tinal exposure compared to photon-based radiotherapyin the treatment of abdominal malignancies [8,9]. The
same principles described in the aforementioned studies
allowed for significant normal-tissue sparing in this case.
In addition to allowing for the delivery of a radiation
dose adequate to secure disease control while avoiding
renal and gastrointestinal toxicity, PT also was associated
with a significant reduction in total-body radiation ex-
posure compared to the exposure associated with IMRT.
Since the correlation between radiation exposure and
radiation-induced second malignancies is well estab-
lished [10-21], and a survival time of 10 years or longer
is not uncommon for patients with DTs, reducing the
body volume receiving low-dose radiation may be of par-
ticular importance in patients for whom a high rate of
disease control and long-term survival is expected.
Conclusion
Proton therepy in this case allowed for the delivery of a
radiation dose adequate to achieve local control without
exposing the patient to renal or gastrointestinal toxicity.
Our pretreatment dosimetry indicated that such a favor-
able outcome could not have been achieved with IMRT.
PT in this case was also associated with a lower integral
total body dose than would have been associated with
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in reducing the risk of late iatrogenic malignancy in a
young patient.
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